IL1RN基因新变异(DIRA)关联晚发型CRMO样表现
一例3岁男孩以反复发热、浆膜炎、胰腺炎及高炎症标志物起病,3岁时出现跛行,影像示多灶性骨盆炎症提示CRMO。全外显子测序发现IL1RN纯合新变异(c.62C>G; p.Ser21*),功能分析确诊IL-1受体拮抗剂缺陷(DIRA)。阿那白滞素治疗快速缓解,换用卡那奴单抗6周内复发,重启阿那白滞素再次缓解并维持19个月。
要点
- 晚发型DIRA可表现为CRMO样骨病变及多系统炎症,而无皮肤表现。
- 对系统性炎症伴CRMO样骨病变者,应考虑IL1RN基因检测。
- 非选择性IL-1抑制剂阿那白滞素有效,选择性IL-1β拮抗剂可能不足。
核心结论
- 首次报道经 advanced diagnostic testing 确诊的晚发型DIRA,由IL1RN新纯合变异(c.62C>G; p.Ser21*)所致。
- 非选择性IL-1抑制(阿那白滞素)有效,而选择性IL-1β拮抗(卡那奴单抗)切换后6周内复发。
研究设计与样本
- 单例病例报告:3岁男孩,13月龄起病,表现为反复发热、浆膜炎、胰腺炎及高炎症标志物。
- 采用全外显子测序(WES)及 advanced IL-1 pathway analysis,并对IL1RN mRNA与IL-1RA蛋白行功能分析。
主要发现
- WES发现IL1RN纯合新变异(c.62C>G; p.Ser21*)(NM_173842.2)。
- 功能分析证实IL1RN mRNA与IL-1RA蛋白缺陷,确诊DIRA。
- 3岁时跛行,影像示多灶性骨盆骨炎症提示CRMO;auto-inflammation panel testing无贡献。
- 阿那白滞素治疗快速缓解;换用卡那奴单抗6周内复发;重启阿那白滞素再次缓解,末次随访19个月。
关键数值与推荐
- IL1RN变异:c.62C>G; p.Ser21*(NM_173842.2),纯合。
- 卡那奴单抗切换后6周内复发;阿那白滞素再治疗后缓解维持至19个月随访。
临床怎么用
- 对系统性炎症伴CRMO样骨病变患者,即使无皮肤表现,也应考虑IL1RN基因检测。
- 确诊DIRA后,非选择性IL-1抑制(阿那白滞素)为有效治疗选择。
局限性
- 单例病例报告,证据级别有限。
- 随访至19个月,长期疗效与安全性未充分评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report a chronic recurrent multifocal osteomyelitis (CRMO)-like clinical phenotype with multisystem inflammation associated with a novel gene variant in the spectrum of IL-1-mediated diseases. METHODS: A 3-year-old boy presented with recurrent episodes of fever, serositis, pancreatitis and high inflammatory markers with onset at age 13 months. At age 3 years, he started limping. Imaging revealed multifocal pelvic bone inflammation suggestive of CRMO. Autoinflammation panel testing was non-contributory. Whole exome sequencing (WES) and advanced IL-1 pathway analysis was conducted. RESULTS: WES identified a novel homozygous interleukin receptor 1 (IL1RN) variant (c.62C>G; p. Ser21*) (NM_173842.2). Functional analysis of IL1RN mRNA and IL-1 receptor antagonist (IL-1RA) protein confirmed the diagnosis of a deficiency of the IL-1 receptor antagonist (DIRA). Treatment with the nonselective IL-1 inhibitor anakinra resulting in rapid remission; switch to the selective IL-1β antagonist canakinumab led to a flare within 6 weeks. Re-start of anakinra recaptured remission, last documented at the recent 19-month follow-up. CONCLUSION: This is the first report of a novel late-onset DIRA confirmed by advanced diagnostic testing. In patients with systemic inflammation and CRMO-like bone lesions, IL1RN testing should be considered; even in the absence of skin manifestations. Non-selective IL-1 inhibition is an effective therapy.
引用
- Kuemmerle-Deschner JB, Welzel T, Hoertnagel K, et al. New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation. Rheumatology (Oxford). 2020. PMID: 32259833. doi:10.1093/rheumatology/keaa119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。